Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
A 1,491-patient study shows overall survival was longer with the docetaxel arm over the TAC and FAC regimens. The approval is the second new indication for Taxotere in the last three months.
You may also be interested in...
Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere
American Pharmaceutical Partners plans to begin shipping Abraxane (nanoparticle albumin-bound paclitaxel) within 45 days. Based on data presented at the American Society of Clinical Oncology meeting, Abraxane demonstrated a cost-benefit to Bristol's Taxol and Aventis' Taxotere for treatment of breast cancer.
Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere
American Pharmaceutical Partners plans to begin shipping Abraxane (nanoparticle albumin-bound paclitaxel) within 45 days. Based on data presented at the American Society of Clinical Oncology meeting, Abraxane demonstrated a cost-benefit to Bristol's Taxol and Aventis' Taxotere for treatment of breast cancer.
Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival
While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.